Skip to content
OpenCapital
Get started

Amneal Pharmaceuticals, Inc. AMRX Institutional — Net revenue

Other product segments

Subtotal dosage forms
$417.92M+1.1%
Oral solid
$171.1M-4.4%
Subtotal therapeutic classes
$133.27M+23.1%
Distribution
$89.15M-15.0%
Central nervous system
$83.38M+23.3%
Transdermal
$73.96M+71.8%
Government label
$59.95M+19.6%
Injectable
$49.94M+43.5%
Other dosage forms
$46.61M-17.4%
Auto-Injector
$41.91M-13.0%
Hormonal / allergy
$35.93M+5.1%
Biosimilar
$22.3M-21.9%
Other therapeutic classes
$13.95M+115%
Oral liquid
$12.09M-48.6%
International
$5.32M+331%

Similar metrics at other companies

Coinbase Global, Inc. logo
COINInstitutional, net — Revenue
$135.73M+37.3%
StoneX Group Inc. logo
SNEXInstitutional — Total revenues
$868.4M+54.7%
Morgan Stanley logo
MSInstitutional Securities1 — Net revenues
$10.72B+19.3%
Jackson Financial logo
JXNInstitutional Products — Total revenues
$143M+23.3%
StoneX Group Inc. logo
SNEXInstitutional — Total operating revenues
$868.4M+54.7%
Stifel Financial logo
SFInstitutional Group — Revenues Net Of Interest Expense
$495.26M+28.7%

Other financials

Income statement

See full
Revenue$722.5M+3.9%
Gross profit$320.1M+25.1%
Operating income$141.8M+41.3%
Net income$62.3M+411%
EPS (diluted)$0.19+375%

Balance sheet

See full
Cash & equivalents$197.7M+234%
Total debt$2.6B+17.7%
Total equity-$45.4M+65.5%
Total assets$3.5B+5.2%

Cash flow

See full
Operating cash flow-$26.7M-461%
CapEx$8.2M-37.9%
Free cash flow-$34.9M-507%

Valuation

See full
Market cap$5.17B+51.0%
Enterprise value$7.55B+33.4%
P/E42.4×—
P/S1.7×+0.5×

Profitability

See full
Gross margin38.7%+2.0pp
Operating margin14.3%+1.6pp
Net margin4%+3.6pp
FCF margin7.9%-1.0pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity127.9×+119×
Current ratio2.5×+1.1×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s institutional — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s institutional — net revenue?
Amneal Pharmaceuticals, Inc. (AMRX) reported institutional — net revenue of $9.82M in Q1 2026.
How has Amneal Pharmaceuticals, Inc.'s institutional — net revenue changed year-over-year?
Amneal Pharmaceuticals, Inc.'s institutional — net revenue decreased by 10.8% year-over-year, from $11.01M to $9.82M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s institutional — net revenue?
Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s institutional — net revenue has grown at a 8.9% compound annual growth rate (CAGR), from $25.18M to $35.38M.
What does institutional — net revenue mean?
This metric represents the total gross sales generated from the institutional business segment after accounting for returns, allowances, and rebates. It reflects the company's ability to capture market share and monetize its pharmaceutical portfolio through direct sales to hospitals, healthcare systems, and other institutional providers. Monitoring this revenue stream helps investors assess the performance and growth trajectory of the company's B2B healthcare distribution channels.